Due to extremely poor prognosis, pancreatic cancer (PDAC) represents the fourth leading
cause of cancer-related death in Western countries. For more than a decade, gemcitabine …

Pancreatic cancer is one of the deadliest cancers, ranking fourth among cancer-related
deaths. Despite all the major molecular advances and treatment breakthroughs, mainly …

In the past 15 years, we have seen few therapeutic advances for patients with pancreatic
cancer, which is the fourth leading cause of cancer-related death in the United States …

Simple Summary The poor prognosis of pancreatic cancer (PC) is associated with several
factors, such as diagnosis at an advanced stage, early distant metastases, and remarkable …

Of the anticipated 50,000 individuals expected to be diagnosed with pancreatic cancer in
2016, the majority will have metastatic disease. Given the noncurative nature of advanced …

Background: Pancreatic ductal adenocarcinoma (PDAC) is characterised by an extremely
poor overall survival (OS) compared to other solid tumours. As the incidence of the disease …

Metastatic pancreatic cancer: old drugs, new paradigms : Current Opinion in Oncology
Metastatic pancreatic cancer: old drugs, new paradigms : Current Opinion in Oncology Log in or …

Targeted therapies and immunotherapy have changed the face of multiple solid
malignancies, including metastatic melanoma and lung cancer, but no such therapies exist …

Although pancreatic adenocarcinoma is the fourth leading cause of cancer death, only
modest improvement has been observed in the past two decades, single agent gemcitabine …

In the phase III ACCORD 11 trial, FOLFIRINOX was associated with the longest survival ever
reported for patients with metastatic pancreatic cancer (11.1 months). However, toxicities …